2018 and 2019 have seen numerous data updates and news that could affect the management of prostate cancer (PC) in Canada.
The CARE™ Genitourinary (GU) Faculty focuses on framing potentially practice changing GU updates from a Canadian perspective.
The following CARE™ Conference Report from ESMO 2019 focuses on prostate cancer updates and includes content on:
- Metastatic castrate resistant prostate cancer (mCRPC).
- Hormone sensitive prostate cancer (HSPC – term used interchangeably with castrate sensitive prostate cancer or CSPC).
- Drug-drug interactions (DDIs).
- A novel androgen receptor inhibitor for nmCRPC (non-metastatic CRPC) and mCSPC.